Michael J. Doane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael J. Doane has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Amy K. O’sUllivan
Alkermes, Inc., Waltham, USA
3 shared publicationsAdam Jauregui
Cerner Enviza, an Oracle Company, North Kansas City, USA
2 shared publicationsDavid McDonnell
Department of Neuroscience, Alkermes Pharma Ireland Ltd., Dublin, Ireland
2 shared publications- David McDonnell
Alkermes Pharma Ireland Ltd, Dublin, Ireland
2 shared publications Haley S. Friedler
OM1, Inc., Boston, MA, USA
2 shared publicationsHannah Cummings
Alkermes, Inc., Waltham, MA, USA
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2165-2181
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Purpose: OASIS (NCT03919994) was a prospective, observational study designed to provide insights on real-world outcomes associated with atypical long-acting injectable (LAI) antipsychotic medications. Patients and Methods: OASIS (March 2019–January 2023) was conducted across 63 US sites. Adults (≥ 18 years) with schizophrenia who newly initiated one of four atypical LAI antipsychotics (aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone long-acting injection [microsphere formulation]) were enrolled and followed for up to 12 months in routine care. Treatment patterns (reasons for treatment initiation, duration of use, rates of switching/discontinuation) were assessed. Outcomes included Clinical Global Impression–Severity (CGI-S), Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) scale, and patient-reported Glasgow Antipsychotic Side-Effect Scale (GASS) scores. Results are summarized descriptively. Results: Overall, 277 patients with schizophrenia enrolled and received ≥ 1 injection. Most common reasons for initiating atypical LAI antipsychotics at baseline were the presence of persistent psychotic symptoms (50%) and adherence challenges with oral antipsychotics (44%). Mean (SD) time on index treatment was 210.0 (145.3) days. Overall, 130 (47%) patients completed 12 months of follow-up; 74% of them remained on the treatment initiated until the end of study participation. Most study visits were conducted in person and were planned/scheduled versus crisis visits. Mean (SD) baseline CGI-S score was 4.2 (1.1), indicating moderate illness severity; individual CRDPSS symptom scores were mild (mean [SD] delusions score, 2.0 [1.4]; hallucinations, 1.9 [1.4]; negative symptoms, 1.6 [1.3]) at baseline and remained stable after treatment initiation. Antipsychotic side effects were generally absent or mild at baseline (mean [SD] GASS total score, 10.7 [10.3]) and over follow-up. Conclusion: Treatment patterns in this observational study reinforced the real-world utility of atypical LAI antipsychotics in the treatment of schizophrenia. Results suggest that patients initiating treatment remained clinically stable with mostly absent or mild side effects for up to 12 months of follow-up. Plain Language Summary: Atypical long-acting injectable (LAI) antipsychotic medications may be underused in the treatment of schizophrenia. In the Observational Study of Long-Acting Injectables in Schizophrenia (OASIS) study, we wanted to better understand the benefits of these medications in the real world. We followed patients with schizophrenia who started taking one of four atypical LAI antipsychotics: aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone. We looked at patterns of how clinicians and patients used these medications and how patients benefited from treatment for up to 1 year. All patients were treated according to their clinician’s practice of routine care; the recommendation to start treatment and the medication chosen were up to the patients and their clinician. Most patients in the study were treated at a community mental health clinic or private practice, not a hospital. Illness severity was moderate and symptoms were mild at the start of the study. After they started taking an atypical LAI antipsychotic, most patients stayed on the medication that they started. Only a few patients switched to a different medication or stopped taking medication altogether. Despite the COVID-19 pandemic, most healthcare visits were in person and were planned rather than crisis visits. Over the course of up to 1 year of follow-up, illness severity and symptoms were stable, and most patients experienced no or mild side effects from the medication they were taking. These results show the utility of atypical LAI antipsychotic medications for the treatment of patients with schizophrenia in a real-world setting.
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2165-2181
Open AccessTreatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Purpose: OASIS (NCT03919994) was a prospective, observational study designed to provide insights on real-world outcomes associated with atypical long-acting injectable (LAI) antipsychotic medications. Patients and Methods: OASIS (March 2019–January 2023) was conducted across 63 US sites. Adults (≥ 18 years) with schizophrenia who newly initiated one of four atypical LAI antipsychotics (aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone long-acting injection [microsphere formulation]) were enrolled and followed for up to 12 months in routine care. Treatment patterns (reasons for treatment initiation, duration of use, rates of switching/discontinuation) were assessed. Outcomes included Clinical Global Impression–Severity (CGI-S), Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) scale, and patient-reported Glasgow Antipsychotic Side-Effect Scale (GASS) scores. Results are summarized descriptively. Results: Overall, 277 patients with schizophrenia enrolled and received ≥ 1 injection. Most common reasons for initiating atypical LAI antipsychotics at baseline were the presence of persistent psychotic symptoms (50%) and adherence challenges with oral antipsychotics (44%). Mean (SD) time on index treatment was 210.0 (145.3) days. Overall, 130 (47%) patients completed 12 months of follow-up; 74% of them remained on the treatment initiated until the end of study participation. Most study visits were conducted in person and were planned/scheduled versus crisis visits. Mean (SD) baseline CGI-S score was 4.2 (1.1), indicating moderate illness severity; individual CRDPSS symptom scores were mild (mean [SD] delusions score, 2.0 [1.4]; hallucinations, 1.9 [1.4]; negative symptoms, 1.6 [1.3]) at baseline and remained stable after treatment initiation. Antipsychotic side effects were generally absent or mild at baseline (mean [SD] GASS total score, 10.7 [10.3]) and over follow-up. Conclusion: Treatment patterns in this observational study reinforced the real-world utility of atypical LAI antipsychotics in the treatment of schizophrenia. Results suggest that patients initiating treatment remained clinically stable with mostly absent or mild side effects for up to 12 months of follow-up. Plain Language Summary: Atypical long-acting injectable (LAI) antipsychotic medications may be underused in the treatment of schizophrenia. In the Observational Study of Long-Acting Injectables in Schizophrenia (OASIS) study, we wanted to better understand the benefits of these medications in the real world. We followed patients with schizophrenia who started taking one of four atypical LAI antipsychotics: aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone. We looked at patterns of how clinicians and patients used these medications and how patients benefited from treatment for up to 1 year. All patients were treated according to their clinician’s practice of routine care; the recommendation to start treatment and the medication chosen were up to the patients and their clinician. Most patients in the study were treated at a community mental health clinic or private practice, not a hospital. Illness severity was moderate and symptoms were mild at the start of the study. After they started taking an atypical LAI antipsychotic, most patients stayed on the medication that they started. Only a few patients switched to a different medication or stopped taking medication altogether. Despite the COVID-19 pandemic, most healthcare visits were in person and were planned rather than crisis visits. Over the course of up to 1 year of follow-up, illness severity and symptoms were stable, and most patients experienced no or mild side effects from the medication they were taking. These results show the utility of atypical LAI antipsychotic medications for the treatment of patients with schizophrenia in a real-world setting.
- Open Access
- 25 June 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (9) , 4350-4366
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Introduction The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using ALNCD significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using ALNCD. Methods This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo’s Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using ALNCD and had continuous enrollment ≥ 6 months before (baseline) and after (follow-up) initiation were eligible. Treatment patterns were evaluated for 6 months after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared before and after AL initiation using ALNCD. Results Patients who initiated AL using ALNCD in this study (n = 1152) had a mean age of 38.4 years; 35.9% were female. For most patients, their first AL dose was 1064 mg (39.4%) or 882 mg (37.1%); 90.3% received their first AL injection along with ALNCD on the same day. A total of 898 (78.0%) patients subsequently received a second AL dose at any time during follow-up. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all P < 0.001). Proportions of patients with all-cause, MH-related, and schizophrenia-related outpatient visits did not change, whereas the mean number of outpatient visits for each HCRU category increased significantly from baseline to follow-up (all P ≤ 0.007). Conclusions Findings from this real-world study suggest that use of AL initiated with ALNCD results in significant declines in acute HCRU.
- 25 June 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (9) , 4350-4366
Open AccessTreatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia
Introduction The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using ALNCD significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using ALNCD. Methods This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo’s Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using ALNCD and had continuous enrollment ≥ 6 months before (baseline) and after (follow-up) initiation were eligible. Treatment patterns were evaluated for 6 months after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared before and after AL initiation using ALNCD. Results Patients who initiated AL using ALNCD in this study (n = 1152) had a mean age of 38.4 years; 35.9% were female. For most patients, their first AL dose was 1064 mg (39.4%) or 882 mg (37.1%); 90.3% received their first AL injection along with ALNCD on the same day. A total of 898 (78.0%) patients subsequently received a second AL dose at any time during follow-up. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all P < 0.001). Proportions of patients with all-cause, MH-related, and schizophrenia-related outpatient visits did not change, whereas the mean number of outpatient visits for each HCRU category increased significantly from baseline to follow-up (all P ≤ 0.007). Conclusions Findings from this real-world study suggest that use of AL initiated with ALNCD results in significant declines in acute HCRU.
- 2 January 2025
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 86 (1)
Olanzapine/Samidorphan Effects on Weight Gain
Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over 12 weeks.
- 2 January 2025
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 86 (1)
Olanzapine/Samidorphan Effects on Weight Gain
Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over 12 weeks.
- Open Access
- 10 September 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-10
Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
Background: Antipsychotic medications are effective treatments for schizophrenia (SZ) and bipolar I disorder (BD-I), but when presented with different treatment options, there are tradeoffs that individuals make between clinical improvement and adverse effects. As new options become available, understanding the attributes of antipsychotic medications that are valued and the tradeoffs that individuals consider when choosing among them is important. Methods: A discrete-choice experiment (DCE) was administered online to elicit preferences across 5 attributes of oral antipsychotics: treatment efficacy (i.e., improvement in symptom severity), weight gain over 6 months, sexual dysfunction, sedation, and akathisia. Eligible respondents were aged 18–64 years with a self-reported clinician diagnosis of SZ or BD-I. Results: In total, 144 respondents with SZ and 152 with BD-I completed the DCE. Of those with SZ, 50% identified themselves as female and 69.4% as White, with a mean (SD) age of 41.0 (10.1) years. Of those with BD-I, most identified themselves as female (69.7%) and as White (77.6%), with a mean (SD) age of 40.0 (10.7) years. In both cohorts, respondents preferred oral antipsychotics with better efficacy, less weight gain, no sexual dysfunction or akathisia, and lower risk of sedation. Treatment efficacy was the most important attribute, with a conditional relative importance (CRI) of 31.4% for respondents with SZ and 31.0% for those with BD-I. Weight gain (CRI = 21.3% and 23.1%, respectively) and sexual dysfunction (CRI = 23.4% and 19.2%, respectively) were adverse effects in this study that respondents most wanted to avoid. Respondents with SZ were willing to accept 9.8 lb of weight gain or > 25% risk of sedation for symptom improvement; those with BD-I were willing to accept 8.5 lb of weight gain or a > 25% risk of sedation. Conclusions: In this DCE, treatment efficacy was the most important attribute of oral antipsychotic medications among respondents with SZ and BD-I. Weight gain and sexual dysfunction were the adverse effects respondents most wanted to avoid; however, both cohorts were willing to accept some weight gain or sedation to obtain better efficacy. These results highlight features that patients value in antipsychotic medications and how they balance benefits and risks when choosing among treatments.
- 10 September 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-10
Open AccessPreferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
Background: Antipsychotic medications are effective treatments for schizophrenia (SZ) and bipolar I disorder (BD-I), but when presented with different treatment options, there are tradeoffs that individuals make between clinical improvement and adverse effects. As new options become available, understanding the attributes of antipsychotic medications that are valued and the tradeoffs that individuals consider when choosing among them is important. Methods: A discrete-choice experiment (DCE) was administered online to elicit preferences across 5 attributes of oral antipsychotics: treatment efficacy (i.e., improvement in symptom severity), weight gain over 6 months, sexual dysfunction, sedation, and akathisia. Eligible respondents were aged 18–64 years with a self-reported clinician diagnosis of SZ or BD-I. Results: In total, 144 respondents with SZ and 152 with BD-I completed the DCE. Of those with SZ, 50% identified themselves as female and 69.4% as White, with a mean (SD) age of 41.0 (10.1) years. Of those with BD-I, most identified themselves as female (69.7%) and as White (77.6%), with a mean (SD) age of 40.0 (10.7) years. In both cohorts, respondents preferred oral antipsychotics with better efficacy, less weight gain, no sexual dysfunction or akathisia, and lower risk of sedation. Treatment efficacy was the most important attribute, with a conditional relative importance (CRI) of 31.4% for respondents with SZ and 31.0% for those with BD-I. Weight gain (CRI = 21.3% and 23.1%, respectively) and sexual dysfunction (CRI = 23.4% and 19.2%, respectively) were adverse effects in this study that respondents most wanted to avoid. Respondents with SZ were willing to accept 9.8 lb of weight gain or > 25% risk of sedation for symptom improvement; those with BD-I were willing to accept 8.5 lb of weight gain or a > 25% risk of sedation. Conclusions: In this DCE, treatment efficacy was the most important attribute of oral antipsychotic medications among respondents with SZ and BD-I. Weight gain and sexual dysfunction were the adverse effects respondents most wanted to avoid; however, both cohorts were willing to accept some weight gain or sedation to obtain better efficacy. These results highlight features that patients value in antipsychotic medications and how they balance benefits and risks when choosing among treatments.
- Open Access
- 8 August 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (10) , 3807-3819
Matched Comparison Examining the Effect of Obesity on Clinical, Economic, and Humanistic Outcomes in Patients with Bipolar I Disorder
Introduction Bipolar I disorder (BD-I) is associated with an increased risk of obesity, but few studies have evaluated the real-world clinical, humanistic, and economic effects associated with obesity in people with BD-I. Methods This was a retrospective, cross-sectional analysis of responses to the 2016 and 2020 National Health and Wellness surveys. Respondents (18–64 years) with a self-reported physician diagnosis of BD-I were matched to controls without BD-I based on demographic and health characteristics. Respondents were categorized by body mass index as underweight/normal weight (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obese (≥ 30 kg/m2). Multivariable regression models were used to compare obesity-related comorbidities, healthcare resource utilization (HCRU), health-related quality of life (HRQoL), work productivity, and indirect and direct costs. Results Before matching, the BD-I cohort was younger than the non-BD-I cohort and included more female and white respondents and a greater proportion covered by Medicaid or Medicare. After matching, the BD-I and non-BD-I cohorts had similar characteristics. A total of 5418 respondents (BD-I, n = 1806; matched controls, n = 3612) were analyzed. Obese respondents with BD-I reported the highest adjusted prevalences of high blood pressure (50%), high cholesterol (35%), sleep apnea (27%), osteoarthritis (17%), type 2 diabetes (12%), and liver disease (4%). Obesity in respondents with BD-I was associated with the lowest HRQoL scores. Measures of work impairment were highest in respondents with BD-I and obesity, as was HCRU. Respondents with BD-I and obesity had the highest associated total indirect and direct medical costs ($25,849 and $44,482, respectively). Conclusion Obese respondents with BD-I had greater frequencies of obesity-related comorbidities, higher HCRU, lower HRQoL, greater work impairments, and higher indirect and direct medical costs. These findings highlight the real-world burden of obesity in people with BD-I and the importance of considering treatments that may reduce this burden.
- 8 August 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (10) , 3807-3819
Open AccessMatched Comparison Examining the Effect of Obesity on Clinical, Economic, and Humanistic Outcomes in Patients with Bipolar I Disorder
Introduction Bipolar I disorder (BD-I) is associated with an increased risk of obesity, but few studies have evaluated the real-world clinical, humanistic, and economic effects associated with obesity in people with BD-I. Methods This was a retrospective, cross-sectional analysis of responses to the 2016 and 2020 National Health and Wellness surveys. Respondents (18–64 years) with a self-reported physician diagnosis of BD-I were matched to controls without BD-I based on demographic and health characteristics. Respondents were categorized by body mass index as underweight/normal weight (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obese (≥ 30 kg/m2). Multivariable regression models were used to compare obesity-related comorbidities, healthcare resource utilization (HCRU), health-related quality of life (HRQoL), work productivity, and indirect and direct costs. Results Before matching, the BD-I cohort was younger than the non-BD-I cohort and included more female and white respondents and a greater proportion covered by Medicaid or Medicare. After matching, the BD-I and non-BD-I cohorts had similar characteristics. A total of 5418 respondents (BD-I, n = 1806; matched controls, n = 3612) were analyzed. Obese respondents with BD-I reported the highest adjusted prevalences of high blood pressure (50%), high cholesterol (35%), sleep apnea (27%), osteoarthritis (17%), type 2 diabetes (12%), and liver disease (4%). Obesity in respondents with BD-I was associated with the lowest HRQoL scores. Measures of work impairment were highest in respondents with BD-I and obesity, as was HCRU. Respondents with BD-I and obesity had the highest associated total indirect and direct medical costs ($25,849 and $44,482, respectively). Conclusion Obese respondents with BD-I had greater frequencies of obesity-related comorbidities, higher HCRU, lower HRQoL, greater work impairments, and higher indirect and direct medical costs. These findings highlight the real-world burden of obesity in people with BD-I and the importance of considering treatments that may reduce this burden.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 15, 681-689
Clinical, Economic, and Humanistic Outcomes Associated with Obesity Among People with Bipolar I Disorder in the United States: Analysis of National Health and Wellness Survey Data
Introduction: People living with bipolar I disorder (BD-I) have an increased risk for obesity compared with the general population that may be related to genetic, lifestyle, and treatment factors. Few studies have examined possible effects of obesity on those living with BD-I. This study examined relationships between obesity and clinical, humanistic, and economic outcomes among adults with BD-I. Methods: This retrospective, cross-sectional study analyzed survey responses from a nationally representative sample of US adults participating in the 2016 or 2020 National Health and Wellness Survey. Respondents (18– 64 years) with a self-reported physician diagnosis of BD-I were included and categorized by body mass index: underweight/normal weight (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obese (≥ 30 kg/m2). Adjusted analyses assessed comorbidities, health-related quality of life (HRQoL), work productivity, health care resource utilization (HCRU), and economic outcomes. Results: In total, responses from 1,853 participants were analyzed; most were female (65%) and white (62%). Respondents with obesity had the highest prevalence of medical comorbidities, including high blood pressure (52%), sleep apnea (37%), hypercholesterolemia (34%), and type 2 diabetes (12%). Obesity was generally associated with the lowest scores of physical health and HRQoL. Activity impairment scores were highest among respondents with obesity, as were numbers of hospitalizations and emergency department visits in the previous 6 months. Respondents with obesity incurred higher annual indirect and direct medical costs ($28,178 and $37,771, respectively) when compared with the underweight/normal weight ($23,823 and $32,227, respectively) and overweight ($24,312 and $35,231, respectively) groups. Conclusion: In this nationally representative sample, obesity was associated with several outcomes that may negatively affect people living with BD-I, including medical comorbidities, higher HCRU, HRQoL impairments, and greater indirect and direct medical costs. These findings highlight the importance of considering the presence of or risk for obesity and associated medical comorbidities when treating BD-I.
- 1 September 2023
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 15, 681-689
Open AccessClinical, Economic, and Humanistic Outcomes Associated with Obesity Among People with Bipolar I Disorder in the United States: Analysis of National Health and Wellness Survey Data
Introduction: People living with bipolar I disorder (BD-I) have an increased risk for obesity compared with the general population that may be related to genetic, lifestyle, and treatment factors. Few studies have examined possible effects of obesity on those living with BD-I. This study examined relationships between obesity and clinical, humanistic, and economic outcomes among adults with BD-I. Methods: This retrospective, cross-sectional study analyzed survey responses from a nationally representative sample of US adults participating in the 2016 or 2020 National Health and Wellness Survey. Respondents (18– 64 years) with a self-reported physician diagnosis of BD-I were included and categorized by body mass index: underweight/normal weight (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obese (≥ 30 kg/m2). Adjusted analyses assessed comorbidities, health-related quality of life (HRQoL), work productivity, health care resource utilization (HCRU), and economic outcomes. Results: In total, responses from 1,853 participants were analyzed; most were female (65%) and white (62%). Respondents with obesity had the highest prevalence of medical comorbidities, including high blood pressure (52%), sleep apnea (37%), hypercholesterolemia (34%), and type 2 diabetes (12%). Obesity was generally associated with the lowest scores of physical health and HRQoL. Activity impairment scores were highest among respondents with obesity, as were numbers of hospitalizations and emergency department visits in the previous 6 months. Respondents with obesity incurred higher annual indirect and direct medical costs ($28,178 and $37,771, respectively) when compared with the underweight/normal weight ($23,823 and $32,227, respectively) and overweight ($24,312 and $35,231, respectively) groups. Conclusion: In this nationally representative sample, obesity was associated with several outcomes that may negatively affect people living with BD-I, including medical comorbidities, higher HCRU, HRQoL impairments, and greater indirect and direct medical costs. These findings highlight the importance of considering the presence of or risk for obesity and associated medical comorbidities when treating BD-I.
- Open Access
- 1 August 2023
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 13 (4) , 196-197
Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
Dear Editor:A recent systematic review by Laguado and Saklad highlighted the importance of addressing olanzapine-associated weight gain.1 While highly efficacious, olanzapine use has been limited by its propensity to cause significant weight gain. The authors considered the role of opioid antagonists in this setting by reviewing efficacy and safety data from the clinical development program of combination olanzapine and samidorphan (OLZ/SAM), concluding in part that samidorphan effectively mitigates olanzapine-associated weight gain. We provide comments on the authors' methodology, as their conclusions may underestimate weight gain mitigation with OLZ/SAM.We suggest that a more precise estimate of OLZ/SAM's weight mitigation benefit would be obtained by (1) analyzing separately the studies that were of sufficient duration to detect differences in weight gain from those that were not, and (2) weighting these study results before calculating the mitigating effect of OLZ/SAM on olanzapine-associated weight gain.Trials by Martin et al, Correll et al, and Kahn et al were of adequate duration (12, 24, and 12 weeks, respectively) to evaluate the targeted differences in treatment-associated weight gain between OLZ/SAM and olanzapine.2-4 In each of these studies, weight gain trajectories for OLZ/SAM and olanzapine were initially similar but then diverged between 4 and 6 weeks of treatment, after which weight gain plateaued in OLZ/SAM-treated patients but continued to increase over time in olanzapine-treated patients. Silverman et al and Potkin et al conducted 3-week and 4-week studies, respectively, that were not of suitable duration to use in calculations of the weight mitigation benefit of OLZ/SAM.5,6Additionally, to obtain a more precise estimate of OLZ/SAM's weight mitigation benefit, the results should be weighted by the sample size of each study. Aggregating outcomes of different studies without considering differences in sample sizes can lead to inaccurate estimates of an intervention's magnitude of effect7,8 that are avoided by using accepted weighting procedures.7Furthermore, in discerning the true weight mitigation benefit of OLZ/SAM, only studies combining 10 mg of samidorphan with olanzapine are of relevance, as 10 mg is the only dose approved by the United States Food and Drug Administration for use in OLZ/SAM. Last, the description of the number needed to harm (NNH) may be misinterpreted by readers as harm associated with the use of OLZ/SAM because the authors did not present NNH as a negative value. By convention, the use of either a negative NNH or the number needed to treat (NNT), rather than NNH, would communicate more clearly the treatment benefit (ie, the weight-mitigating effect of treatment with OLZ/SAM compared with olanzapine).Given these considerations and based on studies that were of sufficient duration and designed to evaluate weight gain in patients with serious mental illness, OLZ/SAM's weight mitigation benefit versus olanzapine ranged from −1.33 to −1.9 kg in trials lasting 12 to 24 weeks2-4; however, the benefit may be greater over longer treatment durations because weight gain plateaus with OLZ/SAM treatment but continues to increase with olanzapine treatment.In summary, the methodologies used by the authors may have underestimated the weight-mitigating effect of OLZ/SAM on olanzapine-associated weight gain.1 To assess the magnitude of this effect accurately, only studies of duration sufficient for assessing this outcome should be included, results of included studies should be weighted, and estimates of effect size should be calculated. Finally, while olanzapine-associated weight gain tends to continue over the long-term, results from open-label studies suggest that weight gain stabilizes during long-term OLZ/SAM treatment.9,10 Further characterizing the weight gain mitigation effect provided by OLZ/SAM versus olanzapine during treatment courses longer than 6 months' duration may be beneficial to clinicians and to patients, many of whom require long-term and continuous antipsychotic treatment.11
- 1 August 2023
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 13 (4) , 196-197
Open AccessComment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
Dear Editor:A recent systematic review by Laguado and Saklad highlighted the importance of addressing olanzapine-associated weight gain.1 While highly efficacious, olanzapine use has been limited by its propensity to cause significant weight gain. The authors considered the role of opioid antagonists in this setting by reviewing efficacy and safety data from the clinical development program of combination olanzapine and samidorphan (OLZ/SAM), concluding in part that samidorphan effectively mitigates olanzapine-associated weight gain. We provide comments on the authors' methodology, as their conclusions may underestimate weight gain mitigation with OLZ/SAM.We suggest that a more precise estimate of OLZ/SAM's weight mitigation benefit would be obtained by (1) analyzing separately the studies that were of sufficient duration to detect differences in weight gain from those that were not, and (2) weighting these study results before calculating the mitigating effect of OLZ/SAM on olanzapine-associated weight gain.Trials by Martin et al, Correll et al, and Kahn et al were of adequate duration (12, 24, and 12 weeks, respectively) to evaluate the targeted differences in treatment-associated weight gain between OLZ/SAM and olanzapine.2-4 In each of these studies, weight gain trajectories for OLZ/SAM and olanzapine were initially similar but then diverged between 4 and 6 weeks of treatment, after which weight gain plateaued in OLZ/SAM-treated patients but continued to increase over time in olanzapine-treated patients. Silverman et al and Potkin et al conducted 3-week and 4-week studies, respectively, that were not of suitable duration to use in calculations of the weight mitigation benefit of OLZ/SAM.5,6Additionally, to obtain a more precise estimate of OLZ/SAM's weight mitigation benefit, the results should be weighted by the sample size of each study. Aggregating outcomes of different studies without considering differences in sample sizes can lead to inaccurate estimates of an intervention's magnitude of effect7,8 that are avoided by using accepted weighting procedures.7Furthermore, in discerning the true weight mitigation benefit of OLZ/SAM, only studies combining 10 mg of samidorphan with olanzapine are of relevance, as 10 mg is the only dose approved by the United States Food and Drug Administration for use in OLZ/SAM. Last, the description of the number needed to harm (NNH) may be misinterpreted by readers as harm associated with the use of OLZ/SAM because the authors did not present NNH as a negative value. By convention, the use of either a negative NNH or the number needed to treat (NNT), rather than NNH, would communicate more clearly the treatment benefit (ie, the weight-mitigating effect of treatment with OLZ/SAM compared with olanzapine).Given these considerations and based on studies that were of sufficient duration and designed to evaluate weight gain in patients with serious mental illness, OLZ/SAM's weight mitigation benefit versus olanzapine ranged from −1.33 to −1.9 kg in trials lasting 12 to 24 weeks2-4; however, the benefit may be greater over longer treatment durations because weight gain plateaus with OLZ/SAM treatment but continues to increase with olanzapine treatment.In summary, the methodologies used by the authors may have underestimated the weight-mitigating effect of OLZ/SAM on olanzapine-associated weight gain.1 To assess the magnitude of this effect accurately, only studies of duration sufficient for assessing this outcome should be included, results of included studies should be weighted, and estimates of effect size should be calculated. Finally, while olanzapine-associated weight gain tends to continue over the long-term, results from open-label studies suggest that weight gain stabilizes during long-term OLZ/SAM treatment.9,10 Further characterizing the weight gain mitigation effect provided by OLZ/SAM versus olanzapine during treatment courses longer than 6 months' duration may be beneficial to clinicians and to patients, many of whom require long-term and continuous antipsychotic treatment.11
- Open Access
- 12 April 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-11
Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups
Background: Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health disorders often treated with antipsychotic medications. This qualitative study sought to better understand disease burden and treatment experiences with oral antipsychotic medications in participants living with SZ or BD-I. Methods: Six 90-min focus groups were conducted with participants diagnosed with SZ or BD-I. Trained moderators facilitated discussions using a semistructured guide. Participants described symptoms, impacts of disease, and experiences with oral antipsychotic medications, whether favourable or unfavourable. Results: Among participants with SZ (n = 15; 3 groups, 5 per group), 53% were male and 33% were white, with a mean of 18.6 years since diagnosis. Of participants with BD-I (n = 24; 3 groups, 8 per group), 33% were male and 42% were white, with a mean of 13.0 years since diagnosis. Participants described numerous symptoms of their illnesses that impacted relationships and daily life, including effects on emotional health, the ability to work, and encounters with law enforcement. Previous antipsychotic medications were deemed effective by 14/15 (93%) participants with SZ and 12/16 (75%) participants with BD-I. Most participants with SZ (13/15; 87%) or with BD-I (16/24; 67%) reported discontinuing their antipsychotic medication at some point. Side effects were a common reason for discontinuing or switching medications for participants with SZ (8/15; 53%) and for those with BD-I (11/24; 46%). The most common side effects reported in both cohorts were weight gain, drowsiness, sexual problems, and neurologic symptoms. Side effects negatively affected quality of life, leading to serious health problems and issues with self-esteem. Conclusions: People living with SZ or BD-I cited a range of favourable and unfavourable experiences with oral antipsychotic medications. Most participants reported that their antipsychotics were effective at controlling their symptoms, but multiple side effects impacted their quality of life, caused additional serious health problems, and often led to discontinuation of or switching antipsychotics. Findings from this study contribute to a better understanding of patients’ experiences with antipsychotics and highlight a need for new medications with favourable benefit/risk profiles.
- 12 April 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-11
Open AccessUnmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups
Background: Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health disorders often treated with antipsychotic medications. This qualitative study sought to better understand disease burden and treatment experiences with oral antipsychotic medications in participants living with SZ or BD-I. Methods: Six 90-min focus groups were conducted with participants diagnosed with SZ or BD-I. Trained moderators facilitated discussions using a semistructured guide. Participants described symptoms, impacts of disease, and experiences with oral antipsychotic medications, whether favourable or unfavourable. Results: Among participants with SZ (n = 15; 3 groups, 5 per group), 53% were male and 33% were white, with a mean of 18.6 years since diagnosis. Of participants with BD-I (n = 24; 3 groups, 8 per group), 33% were male and 42% were white, with a mean of 13.0 years since diagnosis. Participants described numerous symptoms of their illnesses that impacted relationships and daily life, including effects on emotional health, the ability to work, and encounters with law enforcement. Previous antipsychotic medications were deemed effective by 14/15 (93%) participants with SZ and 12/16 (75%) participants with BD-I. Most participants with SZ (13/15; 87%) or with BD-I (16/24; 67%) reported discontinuing their antipsychotic medication at some point. Side effects were a common reason for discontinuing or switching medications for participants with SZ (8/15; 53%) and for those with BD-I (11/24; 46%). The most common side effects reported in both cohorts were weight gain, drowsiness, sexual problems, and neurologic symptoms. Side effects negatively affected quality of life, leading to serious health problems and issues with self-esteem. Conclusions: People living with SZ or BD-I cited a range of favourable and unfavourable experiences with oral antipsychotic medications. Most participants reported that their antipsychotics were effective at controlling their symptoms, but multiple side effects impacted their quality of life, caused additional serious health problems, and often led to discontinuation of or switching antipsychotics. Findings from this study contribute to a better understanding of patients’ experiences with antipsychotics and highlight a need for new medications with favourable benefit/risk profiles.
- Open Access
- 18 July 2022
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (9) , 3933-3956
Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States
Background Schizophrenia is a chronic mental disorder associated with substantial morbidity and mortality affecting 0.25–1.6% of adults in the USA. Antipsychotic treatment is the standard of care for schizophrenia, but real-world treatment patterns and associated costs have not been systematically reviewed. Objective We conducted a systematic review to summarize treatment patterns and associated costs related to oral antipsychotic treatment of patients with schizophrenia in the USA. Data Sources We searched Medline (via PubMed) and Embase to identify relevant observational studies published from January 1, 2008, to June 1, 2018; costs were converted to 2018 US dollars. Study Eligibility Observational, real-world studies reporting on patterns of treatment and/or associated costs for adult patients with schizophrenia treated with oral antipsychotics in the USA were included. Results Eighty-one studies were identified. Frequently prescribed oral second-generation antipsychotics were olanzapine (up to 50.9%), risperidone (up to 40.0%), and quetiapine (up to 30.7%). Suboptimal adherence was common across studies. Antipsychotic switching occurred in about half of patients, while antipsychotic combination therapy occurred in nearly 30%; all were associated with increased medication-related costs. Mean annual direct medical costs differed by treatment, with reported costs of $17,115 to $26,138 for patients treated with olanzapine, $18,395 for risperidone, and $17,656 to $28,101 for quetiapine. Limitations This systematic review is limited by the variations in definitions of schizophrenia-related clinical terms used between studies and by the inclusion of studies focused on only the US health care system. Conclusions In the treatment of schizophrenia, suboptimal adherence, antipsychotic switching, and antipsychotic augmentation were all associated with high costs of care in comparison to patients who were adherent and did not require antipsychotic switching or augmentation. These findings illustrate the need for the development of new treatments that address efficacy and adherence challenges of currently available therapies.
- 18 July 2022
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (9) , 3933-3956
Open AccessSystematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States
Background Schizophrenia is a chronic mental disorder associated with substantial morbidity and mortality affecting 0.25–1.6% of adults in the USA. Antipsychotic treatment is the standard of care for schizophrenia, but real-world treatment patterns and associated costs have not been systematically reviewed. Objective We conducted a systematic review to summarize treatment patterns and associated costs related to oral antipsychotic treatment of patients with schizophrenia in the USA. Data Sources We searched Medline (via PubMed) and Embase to identify relevant observational studies published from January 1, 2008, to June 1, 2018; costs were converted to 2018 US dollars. Study Eligibility Observational, real-world studies reporting on patterns of treatment and/or associated costs for adult patients with schizophrenia treated with oral antipsychotics in the USA were included. Results Eighty-one studies were identified. Frequently prescribed oral second-generation antipsychotics were olanzapine (up to 50.9%), risperidone (up to 40.0%), and quetiapine (up to 30.7%). Suboptimal adherence was common across studies. Antipsychotic switching occurred in about half of patients, while antipsychotic combination therapy occurred in nearly 30%; all were associated with increased medication-related costs. Mean annual direct medical costs differed by treatment, with reported costs of $17,115 to $26,138 for patients treated with olanzapine, $18,395 for risperidone, and $17,656 to $28,101 for quetiapine. Limitations This systematic review is limited by the variations in definitions of schizophrenia-related clinical terms used between studies and by the inclusion of studies focused on only the US health care system. Conclusions In the treatment of schizophrenia, suboptimal adherence, antipsychotic switching, and antipsychotic augmentation were all associated with high costs of care in comparison to patients who were adherent and did not require antipsychotic switching or augmentation. These findings illustrate the need for the development of new treatments that address efficacy and adherence challenges of currently available therapies.
- Open Access
- 28 April 2022
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 27 (2) , 240
Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia
ObjectiveClinically significant weight gain (CSWG) is associated with increased morbidity and mortality. This study describes CSWG and comorbidities observed in patients with bipolar I disorder (BD-I) and schizophrenia (SZ) after initiating select second-generation antipsychotics (SGAs).MethodsPercent change in weight, CSWG (=7% weight increase), and incident comorbidities within 12 months of treatment were assessed among patients initiating oral SGAs of moderate-to-high weight gain risk using medical records/claims (OM1 Real-World Data Cloud; January 2013-February 2020). Oral SGAs included clozapine (SZ), iloperidone (SZ), paliperidone (SZ), olanzapine, olanzapine/fluoxetine (BD-I), quetiapine, and risperidone. Outcomes were stratified by baseline body mass index and reported descriptively.ResultsAmong patients with BD-I (N = 9142) and SZ (N = 8174), approximately three-quarters were overweight/obese at baseline. During treatment (mean duration = 30 weeks), average percent weight increase was 3.7% (BD-I) and 3.3% (SZ). Average percent weight increase was highest for underweight/normal weight patients (BD-I = 5.5%; SZ = 4.8%), followed by overweight (BD-I = 3.8%; SZ = 3.4%) and obese patients (BD-I = 2.7%; SZ = 2.3%). Within 3 months of treatment, 12% of all patients experienced CSWG. A total of 11.3% (BD-I) and 14.7% (SZ) of patients developed coronary artery disease, hypertension, dyslipidemia, or type 2 diabetes within 12 months of treatment; development of comorbidities was highest among overweight/obese patients and those with CSWG.ConclusionsPatients who were underweight/normal weight at baseline had the greatest percent change in weight during treatment. Increased comorbidities were observed within 12 months of treatment, specifically among overweight/obese patients and those with CSWG. The magnitude of weight gain and development of comorbidities were similar for patients with BD-I and SZ.FundingAlkermes, Inc.
- 28 April 2022
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 27 (2) , 240
Open AccessWeight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia
ObjectiveClinically significant weight gain (CSWG) is associated with increased morbidity and mortality. This study describes CSWG and comorbidities observed in patients with bipolar I disorder (BD-I) and schizophrenia (SZ) after initiating select second-generation antipsychotics (SGAs).MethodsPercent change in weight, CSWG (=7% weight increase), and incident comorbidities within 12 months of treatment were assessed among patients initiating oral SGAs of moderate-to-high weight gain risk using medical records/claims (OM1 Real-World Data Cloud; January 2013-February 2020). Oral SGAs included clozapine (SZ), iloperidone (SZ), paliperidone (SZ), olanzapine, olanzapine/fluoxetine (BD-I), quetiapine, and risperidone. Outcomes were stratified by baseline body mass index and reported descriptively.ResultsAmong patients with BD-I (N = 9142) and SZ (N = 8174), approximately three-quarters were overweight/obese at baseline. During treatment (mean duration = 30 weeks), average percent weight increase was 3.7% (BD-I) and 3.3% (SZ). Average percent weight increase was highest for underweight/normal weight patients (BD-I = 5.5%; SZ = 4.8%), followed by overweight (BD-I = 3.8%; SZ = 3.4%) and obese patients (BD-I = 2.7%; SZ = 2.3%). Within 3 months of treatment, 12% of all patients experienced CSWG. A total of 11.3% (BD-I) and 14.7% (SZ) of patients developed coronary artery disease, hypertension, dyslipidemia, or type 2 diabetes within 12 months of treatment; development of comorbidities was highest among overweight/obese patients and those with CSWG.ConclusionsPatients who were underweight/normal weight at baseline had the greatest percent change in weight during treatment. Increased comorbidities were observed within 12 months of treatment, specifically among overweight/obese patients and those with CSWG. The magnitude of weight gain and development of comorbidities were similar for patients with BD-I and SZ.FundingAlkermes, Inc.